Scarica l'app Stockscreener
17.03
0.65%
0.11
Dopo l'orario di chiusura:
17.01
-0.02
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$16.92
Aprire:
$16.77
Volume 24 ore:
1.40M
Relative Volume:
1.79
Capitalizzazione di mercato:
$689.84M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-3.7511
EPS:
-4.54
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
-9.56%
1M Prestazione:
-68.54%
6M Prestazione:
-62.50%
1 anno Prestazione:
-49.59%
Intervallo 1D:
$16.62
$17.64
Intervallo di 1 settimana:
$16.30
$19.65
Portata 52W:
$15.67
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
17.03 | 689.84M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Franklin Resources Inc. Trims Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $81.33 - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - AccessWire
Keros Therapeutics, Inc. (NASDAQ:KROS) Stake Lowered by Y Intercept Hong Kong Ltd - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by State Street Corp - Defense World
(KROS) Investment Analysis and Advice - Stock Traders Daily
Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share - Seeking Alpha
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Keros Therapeutics: Hold Through The Dust - Seeking Alpha
Keros Therapeutics (NASDAQ:KROS) Shares Down 5.7% After Analyst Downgrade - Defense World
Keros Therapeutics (NASDAQ:KROS) Given New $63.00 Price Target at Oppenheimer - Defense World
Keros Therapeutics (NASDAQ:KROS) Trading Down 5.7% After Analyst Downgrade - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down Following Analyst Downgrade - Defense World
Keros Therapeutics shares price target cut on ceased dosing By Investing.com - Investing.com Canada
Where Keros Therapeutics Stands With Analysts - Benzinga
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down on Analyst Downgrade - MarketBeat
Oppenheimer Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $63.00 - MarketBeat
Guggenheim Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat
HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $47.00 - Defense World
Keros Stock Hits Rock Bottom After Pulmonary Hypertension Trial Halt, But Retail Bets On A Rebound - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Scotiabank Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Keros Therapeutics price target raised to $28 from $11 at Wells Fargo - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation - AccessWire
Jefferies sees limited efficacy but keeps Keros Therapeutics stock at Buy - Investing.com
Blow For Keros’s PAH Candidate As Dreams Of Surpassing Winrevair Fade - Citeline
HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
William Blair Downgrades Keros Therapeutics (KROS) - MSN
Traders Purchase High Volume of Keros Therapeutics Call Options (NASDAQ:KROS) - Defense World
TD Cowen Downgrades Keros Therapeutics (KROS) - MSN
TD Cowen cuts Keros Therapeutics stock to Hold on trial concerns - Investing.com Canada
Keros Therapeutics stock hits 52-week low at $18.63 By Investing.com - Investing.com South Africa
Keros Therapeutics shares downgraded to neutral by BTIG on clinical trial - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out - AccessWire
Keros stock plunges 73% on drug study halt over safety concerns (update) - MSN
Keros stock wilts as it halts two dosing arms in hypertension study - BioWorld Online
Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial - Reuters
Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug - Yahoo! Voices
Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff (KROS) - Seeking Alpha
Lexington biotech's stock crashes after partial drug trial pause - The Business Journals
Keros Therapeutics stock hits 52-week low at $18.63 - Investing.com
Keros stock plunges 76% on drug study halt over safety concerns - MSN
Keros Therapeutics (NASDAQ:KROS) Downgraded to Hold Rating by TD Cowen - MarketBeat
Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga
Keros Thera slumps after halting parts of cibotercept trial - The Pharma Letter
Keros Therapeutics (NASDAQ:KROS) Lowered to "Market Perform" Rating by William Blair - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded by BTIG Research to "Neutral" - MarketBeat
Keros Therapeutics Loses 75% Value In A Single SessionHere's Why - Benzinga
Keros Therapeutics halts dosing of blood pressure treatment after safety review - MSN
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Keros Therapeutics Inc Azioni (KROS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):